Cempra to Report Third Quarter 2016 Financial Results
October 25 2016 - 4:15PM
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in
the treatment of bacterial infectious diseases, today announced
that it will report third quarter 2016 financial results after the
close of U.S. financial markets on Thursday, October 27, 2016.
Cempra management will host a webcast and conference call at 5:00
p.m. EDT that day to discuss the financial results and provide a
corporate update.
The live call may be accessed by dialing 877-377-7553 for
domestic callers and 253-237-1151 for international callers and
using conference ID # 7622650. A live webcast of the call will be
available online from the investor relations section of the company
website at www.cempra.com and will be archived there for 30 days. A
telephone replay of the call will be available by dialing
855-859-2056 for domestic callers or 404-537-3406 for international
callers and entering the conference ID # 7622650.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused
on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead
product candidates are currently in advanced clinical development.
Solithromycin has been successfully evaluated in two Phase 3
clinical trials for community acquired bacterial pneumonia (CABP)
and applications for approval for both intravenous and oral capsule
formulations have been accepted for review by the FDA and the EMA.
Solithromycin is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation,
for certain exclusive rights in Japan. Solithromycin is also in a
Phase 3 clinical trial for uncomplicated urogenital urethritis
caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted
with BARDA for the development of solithromycin for pediatric use.
Three formulations, intravenous, oral capsules and a suspension
formulation are in a Phase 1b trial in children from birth to 17
years of age. Fusidic acid is Cempra's second product candidate,
which is being developed for acute bacterial skin and skin
structure infections (ABSSSI) and is also in an exploratory study
for chronic oral treatment of refractory infections in bones and
joints. Both products seek to address the need for new treatments
targeting drug-resistant bacterial infections in the hospital and
in the community. Cempra has also synthesized novel macrolides for
non-antibiotic uses such as the treatment of chronic inflammatory
diseases, endocrine diseases and gastric motility disorders. Cempra
was founded in 2006 and is headquartered in Chapel Hill, N.C. For
additional information about Cempra please visit
www.cempra.com.
Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534
jbluth@cempra.com
Investor Contact:
Robert Uhl
Westwicke Partners, LLC
+1 858 356 5932
robert.uhl@westwicke.com
Media Contact:
Melyssa Weible
Elixir Health PR
+1 201 723 5805
mweible@elixirhealthpr.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Sep 2023 to Sep 2024